Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
A webcast and 90-day replay of management’s Sept. 9 fireside chat will be available on Sagimet’s Investors & Media site.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sagimet Biosciences (SGMT) will participate in two investor conferences in September 2026 in New York. Management joins the Cantor 2026 Global Healthcare Conference on September 9, 2026, including a fireside chat at 1:35 p.m. ET, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. A webcast of the fireside chat and a 90-day replay will be accessible via the Investors & Media section of the company’s website.
Details
News Market Reaction – SGMT
On Sep 2, the day this news came out, SGMT closed 4.76% above the previous close. Our momentum scanner recorded 7 alerts for this stock that day. Relative volume reached 1.6x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.
- Cantor 2026 Global Healthcare Conference in New York, NY on Wednesday, September 9, 2026, with a fireside chat at 1.35pm ET (link here).
- H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on Monday, September 14, 2026.
The fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.